Panel Back's Novo's Diabetes Combo, But Will The Market?
Executive Summary
An FDA advisory panel unanimously backed approval of Novo Nordisk AS' fixed-dose combination of Victoza (liraglutide) and Tresiba (insulin degludec), but if the agency approves the drug, it will be facing a market full of competitors and several other new products coming down the pike.